Champions Oncology to Announce Third Quarter Financial Results on Thursday, March 12, 2026
Rhea-AI Summary
Champions Oncology (NYSE: CSBR) will report third-quarter results for the period ended January 31, 2026, on Thursday, March 12, 2026, after market close. The company will host a conference call the same day at 4:30 P.M. EDT (1:30 P.M. PDT).
Dial-in details: Domestic 888-506-0062, International 973-528-0011, access code 957548. A replay is available for 72 hours by dialing 877-481-4010 (Domestic) or 919-882-2331 (International), passcode 53731, or via the investors section of the company website.
Positive
- None.
Negative
- None.
News Market Reaction – CSBR
In the Mar 6 session, CSBR gained 2.44%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Earnings date Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Dec 08 | Earnings date notice | Neutral | +0.2% | Announced date and call details for Q2 FY2026 results release. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Earnings date announcements have historically produced very small price moves, suggesting limited standalone impact.
Over the past six months, Champions Oncology reported Q1 FY2026 revenue of $14.0 million with margin pressure and an operating loss, followed by record Q2 oncology revenue of about $15.0 million and improved profitability. Prior earnings date releases, such as the Q2 FY2026 scheduling on Dec 8, 2025, saw only a 0.16% move, indicating that investors generally wait for the full results rather than reacting to timing announcements alone.
AI-generated analysis. How Rhea-AI works. Not financial advice.
HACKENSACK, NJ / ACCESS Newswire / March 5, 2026 / Champions Oncology, Inc. (CSBR), a leading translational oncology research organization, will report its financial and operational results for the third quarter ended January 31, 2026, on Thursday, March 12, 2026, after market close. The company will host a conference call to discuss the results that day at 4:30 P.M. EDT (1:30 P.M. PDT). To join the call dial 888-506-0062 (Domestic) or 973-528-0011 (International) and enter the access code 957548. A replay of the call will be available by dialing 877-481-4010 (Domestic) or 919-882-2331 (International) and entering passcode: 53731, or by accessing the investors section of the company's website within 72 hours.
About Champions Oncology, Inc.
Champions Oncology is a global preclinical and clinical research services provider that offers end-to-end oncology R&D solutions to biopharma organizations. With the largest and most annotated bank of clinically relevant patient-derived xenograft (PDX) and primary hematological malignancy models, Champions delivers innovative highest-quality data through proprietary in vivo and ex vivo platforms. Through its large portfolio of cutting-edge bioanalytical platforms, groundbreaking data platform and analytics, and scientific excellence, Champions enables the advancement of preclinical and clinical oncology drug discovery and development programs worldwide. For more information, please visit www.ChampionsOncology.com.
Media Inquiries:
Gavin Cooper
Vice President, Global Marketing
gcooper@championsoncology.com
Website: https://www.championsoncology.com/
Facebook: https://www.facebook.com/championsoncology/
LinkedIn: https://www.linkedin.com/company/champions-oncology-inc-/
Twitter: @ChampionsOncol1
Instagram: https://www.instagram.com/championsoncology/
SOURCE: Champions Oncology, Inc.
View the original press release on ACCESS Newswire